ALLIANCEBERNSTEIN L.P. - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 155 filers reported holding REVANCE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.49 and the average weighting 0.4%.

Quarter-by-quarter ownership
ALLIANCEBERNSTEIN L.P. ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,043,770
-98.4%
91,000
-96.5%
0.00%
-100.0%
Q2 2023$65,711,417
+3.1%
2,596,263
+31.2%
0.03%0.0%
Q1 2023$63,729,321
+3990.4%
1,978,557
+2244.3%
0.03%
+2600.0%
Q4 2022$1,558,024
-50.4%
84,400
-27.5%
0.00%
-50.0%
Q3 2022$3,144,000
+95.4%
116,4470.0%0.00%
+100.0%
Q2 2022$1,609,000
-42.7%
116,447
-19.1%
0.00%0.0%
Q1 2022$2,807,000
+19.7%
143,947
+0.1%
0.00%0.0%
Q4 2021$2,346,000
-97.4%
143,747
-95.6%
0.00%
-97.2%
Q3 2021$91,425,000
-0.1%
3,281,595
+6.3%
0.04%
-2.7%
Q2 2021$91,518,000
-2.4%
3,087,666
-7.9%
0.04%
-9.8%
Q1 2021$93,724,000
+7.9%
3,353,279
+9.4%
0.04%0.0%
Q4 2020$86,888,000
+32.8%
3,065,904
+17.8%
0.04%
+17.1%
Q3 2020$65,452,000
-4.0%
2,603,516
-6.8%
0.04%
-12.5%
Q2 2020$68,200,000
+108.3%
2,792,810
+26.2%
0.04%
+73.9%
Q1 2020$32,740,000
+3.4%
2,212,173
+13.4%
0.02%
+27.8%
Q4 2019$31,664,000
+17.5%
1,950,975
-5.9%
0.02%
+5.9%
Q3 2019$26,952,000
+1.7%
2,073,211
+1.4%
0.02%
+6.2%
Q2 2019$26,508,000
-17.6%
2,043,800
+0.1%
0.02%
-23.8%
Q1 2019$32,168,000
+2.4%
2,041,129
+30.7%
0.02%
-8.7%
Q4 2018$31,427,000
-23.4%
1,561,192
-5.5%
0.02%
-14.8%
Q3 2018$41,051,000
+14.2%
1,651,949
+26.1%
0.03%
+8.0%
Q2 2018$35,961,000
+2.5%
1,310,053
+15.0%
0.02%0.0%
Q1 2018$35,085,000
+8.1%
1,139,111
+25.5%
0.02%
+8.7%
Q4 2017$32,450,000
+5299.3%
907,695
+4063.7%
0.02%
Q3 2017$601,000
-5.2%
21,800
-9.2%
0.00%
Q2 2017$634,000
+27.1%
24,0000.0%0.00%
Q1 2017$499,000
-13.2%
24,000
-13.7%
0.00%
Q4 2016$575,000
+20.5%
27,800
-5.4%
0.00%
Q3 2016$477,000
-0.6%
29,400
-16.7%
0.00%
Q2 2016$480,000
+8.6%
35,300
+39.5%
0.00%
Q1 2016$442,000
-48.8%
25,3000.0%0.00%
-100.0%
Q4 2015$864,000
+30.7%
25,300
+14.0%
0.00%0.0%
Q3 2015$661,000
+3.9%
22,200
+11.6%
0.00%0.0%
Q2 2015$636,000
+326.8%
19,900
+176.4%
0.00%
Q1 2015$149,000
-98.5%
7,200
-98.7%
0.00%
-100.0%
Q4 2014$9,756,000
-2.1%
575,906
+11.7%
0.01%0.0%
Q3 2014$9,967,000
-21.6%
515,614
+37.9%
0.01%
-27.3%
Q2 2014$12,713,000373,9210.01%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q3 2020
NameSharesValueWeighting ↓
Essex Woodlands Management, Inc. 3,342,047$94,714,00024.58%
Palo Alto Investors LP 2,673,313$75,762,0003.97%
Evolutionary Tree Capital Management, LLC 89,348$2,532,0001.93%
RICE HALL JAMES & ASSOCIATES, LLC 1,121,152$31,773,0001.12%
ArrowMark Colorado Holdings LLC 2,964,135$84,004,0000.65%
Rhenman & Partners Asset Management AB 220,000$6,235,0000.51%
Fosun International Ltd 233,841$6,627,0000.43%
OSTERWEIS CAPITAL MANAGEMENT INC 174,970$4,959,0000.30%
ESSEX INVESTMENT MANAGEMENT CO LLC 76,671$2,173,0000.27%
Tekla Capital Management LLC 213,808$6,059,0000.21%
View complete list of REVANCE THERAPEUTICS INC shareholders